Laura Douglass - Odonate Therapeutics Director
Director
Ms. Laura Johnson Douglass serves as Independent Director of the Company. Ms. Douglass has served as a director since December 2018. Ms. Douglass is the President and Chief Executive Officer of Next Generation Clinical Research Consulting, Inc., a contract research organization servicing the pharmaceutical industry that she founded in 1999. Additionally, Ms. Douglass is the President and Chief Executive Officer of Eufaeria Biosciences, Inc., a biotechnology company that she founded in 2016. Since 2013, she has served as a director of La Jolla Pharmaceutical Company. Ms. Douglass is also a founder and director of SB Bancorp, Inc. and Settlers Bank, Inc since 2018.
| Age | 53 |
| Tenure | 6 years |
| Phone | 332 206 0935 |
| Web | https://www.odonate.com |
Odonate Therapeutics Management Efficiency
The company has Return on Asset of (33.09) % which means that on every $100 spent on assets, it lost $33.09. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (86.14) %, meaning that it generated no profit with money invested by stockholders. Odonate Therapeutics' management efficiency ratios could be used to measure how well Odonate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company has 4.85 M in debt with debt to equity (D/E) ratio of 0.07, which may show that the company is not taking advantage of profits from borrowing. Odonate Therapeutics has a current ratio of 3.22, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Odonate Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Odonate Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Odonate Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Odonate to invest in growth at high rates of return. When we think about Odonate Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mark McEachen | BJs Restaurants | 47 | |
| Brenda Lauderback | Dennys Corp | 67 | |
| Christopher Connor | Yum Brands | 65 | |
| Lea Ottinger | BJs Restaurants | 59 | |
| Gregory Maxwell | Jeld Wen Holding | 59 | |
| Nancy Taylor | Topbuild Corp | 61 | |
| Elizabeth Grenfell | Yum Brands | N/A | |
| Larry Bump | EMCOR Group | 74 | |
| Janet Sherlock | BJs Restaurants | 52 | |
| Paget Alves | Yum Brands | 65 | |
| Mirian GraddickWeir | Yum Brands | 65 | |
| Peter Skala | Yum Brands | 60 | |
| Anthony Munk | Jeld Wen Holding | 59 | |
| Carol Lowe | EMCOR Group | 55 | |
| Keith Meister | Yum Brands | 41 | |
| Jonathan Linen | Yum Brands | 70 | |
| Joseph Cantie | Topbuild Corp | 57 | |
| Annie YoungScrivner | Yum Brands | 51 | |
| Thomas Ryan | Yum Brands | 62 | |
| Margaret Whelan | Topbuild Corp | 45 | |
| Michael Yonker | EMCOR Group | 74 | |
Management Performance
| Return On Equity | -86.14 | |||
| Return On Asset | -33.09 |
Odonate Therapeutics Leadership Team
Elected by the shareholders, the Odonate Therapeutics' board of directors comprises two types of representatives: Odonate Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Odonate. The board's role is to monitor Odonate Therapeutics' management team and ensure that shareholders' interests are well served. Odonate Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Odonate Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Valerie Legagneur, Vice President - Clinical Operations | ||
| Aaron Davis, Independent Director | ||
| Natasha BartaschPrice, Vice President - Program Management | ||
| Thomas Wei, Senior Vice President - Research and Strategy | ||
| Nicole Gollaher, Vice President - Legal Affairs | ||
| Stewart Kroll, Senior Vice President - Biometrics | ||
| Laura Douglass, Director | ||
| George Tidmarsh, Director | ||
| Steven Pfeiffer, Vice President - Technical Operations | ||
| Craig Johnson, Independent Director | ||
| Robert Rosen, Director | ||
| Jeff Vacirca, Vice Chairman of the Board | ||
| Robert Millham, COO | ||
| John Lemkey, CFO | ||
| Michael Hearne, CFO | ||
| Joseph OConnell, Chief Medical Officer |
Odonate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Odonate Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -86.14 | |||
| Return On Asset | -33.09 | |||
| Current Valuation | (48.22 M) | |||
| Shares Outstanding | 38.49 M | |||
| Shares Owned By Insiders | 1.81 % | |||
| Shares Owned By Institutions | 65.75 % | |||
| Number Of Shares Shorted | 591.52 K | |||
| Price To Earning | (9.95) X | |||
| Price To Book | 0.60 X | |||
| EBITDA | (80.18 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Odonate Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Odonate Therapeutics' short interest history, or implied volatility extrapolated from Odonate Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Odonate Therapeutics information on this page should be used as a complementary analysis to other Odonate Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Odonate Stock
If you are still planning to invest in Odonate Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Odonate Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |